Financial Snapshot

Revenue
$105.9M
TTM
Gross Margin
7.02%
TTM
Net Earnings
-$110.4M
TTM
Current Assets
Q1 2023
Current Liabilities
Q1 2023
Current Ratio
116.07%
Q1 2023
Total Assets
Q1 2023
Total Liabilities
Q1 2023
Book Value
$55.26M
Q1 2023
Cash
Q1 2023
P/E
-0.000001657
Nov 29, 2024 EST
Free Cash Flow
-$112.0M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $183.00

About ViewRay, Inc.

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The firm has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: ABBOTT LABORATORIES CUTERA INC ANGIODYNAMICS INC ARTIVION, INC. Senseonics Holdings, Inc. Cardiovascular Systems Inc HESKA CORP Outset Medical, Inc. MESA LABORATORIES INC /CO/ SI-BONE, Inc.